Erratum

It was incorrectly reported in the January 20 issue that the methylphenidate skin patch was deemed approvable by an FDA panel for the treatment of attention-deficit/hyperactivity disorder in adults as well as children aged 6 to 12. In fact, approval was sought and obtained for use only in children aged 6 to 12. The patch was developed by Noven Pharmaceuticals and will be marketed jointly by Noven and Shire Pharmaceuticals under the trade name Daytrana. ▪